Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors
| Autor: | Francesco Perri, Raffaele Solla, Morena Fasano, Fortunato Ciardiello, Marco Cascella, Carminia Maria Della Corte, Raimondo Di Liello, Alessandro Ottaiano, Giuseppina Della Vittoria Scarpati |
|---|---|
| Přispěvatelé: | Fasano, M., Perri, F., Corte, C. M. D., Di Liello, R., Scarpati, G. D. V., Cascella, M., Ottaiano, A., Ciardiello, F., Solla, R. |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty QH301-705.5 medicine.medical_treatment Medicine (miscellaneous) Review head and neck squamous cell carcinoma DNA damage response General Biochemistry Genetics and Molecular Biology Internal medicine medicine Biology (General) neoplasms Chemotherapy Cetuximab business.industry Head and neck tumors Immunotherapy medicine.disease Head and neck squamous-cell carcinoma stomatognathic diseases epithelial growth factor receptor Molecular targets Narrative review immunotherapy business medicine.drug |
| Zdroj: | Biomedicines, Vol 9, Iss 1045, p 1045 (2021) Biomedicines |
| ISSN: | 2227-9059 |
| DOI: | 10.3390/biomedicines9081045 |
| Popis: | Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists’ community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|